-
- Tomasz Sacha, Andreas Hochhaus, Benjamin Hanfstein, Martin C Müller, Zbigniew Rudzki, Jacek Czopek, Teresa Wolska-Smoleń, Sylwia Czekalska, Zoriana Salamanchuk, Malgorzata Jakóbczyk, and Aleksander B Skotnicki.
- Department of Haematology, Jagiellonian University Medical College, Cracow, Poland. mmsacha@cyf-kr.edu.pl
- Leuk. Res. 2003 Dec 1; 27 (12): 1163-6.
AbstractImatinib mesylate (STI571) is a major therapeutic advance for the management of chronic myeloid leukaemia (CML), however, a proportion of patients are refractory to it, particularly those in more advanced phases of CML. Different mechanisms of resistance to imatinib are suggested, including point mutations within ABL-kinase domains. A point mutation leading to substitution at the ATP binding site of ABL-kinase and insensitivity to imatinib was detected in our patient treated with imatinib, who progressed to blast crisis. Additionally, clonal evolution could lead to BCR-ABL-independent proliferation. Early detection of ABL-kinase mutation could predict the progression of CML treated with imatinib.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..